Regenerative Medicine Market in the US 2017-2021


◆タイトル:Regenerative Medicine Market in the US 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥364,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。


当調査レポートでは、再生医療のアメリカ市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、再生医療のアメリカ市場規模及び予測、用途別分析、製品別分析、需要先別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は再生医療のアメリカ市場が2017-2021年期間中に年平均23.53%成長すると予測しています。当レポート上に記載されている主な企業は• Acelity• Medtronic• MiMedx• Organogenesis• Zimmer Biomet等です。



About Regenerative Medicine Market in the USRegenerative medicine is a bioproduct, which is developed by using translational research techniques such as molecular biology, tissue engineering, and gene engineering. Stem cells and tissue scaffolds have the effective therapeutic potential, which has increased the adoption of regenerative medicine in the US market. Stem cell therapy responds well to various treatments such as dermatological, macular, musculoskeletal, and cardiovascular applications. The regenerative medicine industry includes four key sectors, which help the vendors to develop regenerative medicine.

Technavio’s analysts forecast the Regenerative Medicine Market in the US to grow at a CAGR of 23.53% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the Regenerative Medicine Market in the US for 2017-2021. To calculate the market size, the report considers the sales, volume, and value of regenerative medicine market in the US.

Technavio’s report, Regenerative Medicine Market in the US 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Acelity
• Medtronic
• MiMedx
• Organogenesis
• Zimmer Biomet

[Other prominent vendors]
• ACE Surgical Supply
• Acera Surgical
• Acologix
• Advanced Biologics
• AlloCure
• AlloSource
• Alphatec Spine
• Antibe Therapeutics
• Astellas Pharma
• Athersys
• Avita Medical
• AxoGen
• Bacterin International
• Baxter
• Bellicum Pharmaceuticals
• BioCardia
• Biogen
• BioRestorative Therapies
• Biostage
• Bio-Tissue
• BioTissue
• bluebird bio
• BrainStorm Cell Therapeutics
• Caladrius
• Calimmune
• Capricor Therapeutics
• Cell Medica
• Cell Therapy
• CellBioMed
• CellSeed
• Celyad
• CryoLife
• Cynata
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• DiscGenics
• Fate Therapeutics
• Fibrocell Science
• Forticell Bioscience
• Fortress Biotech
• FUJIFILM Holdings
• Gamida Cell
• Geron
• GlaxoSmithKline
• Healthpoint (acquired by Smith & Nephew)
• Histogen
• Histogenics
• Holostem Terapie Avanzate
• Humacyte
• Immunocellular Therapeutics
• Integra LifeSciences
• Intercytex
• InVivo Therapeutics
• iSTO Biologics
• Janssen Pharmaceuticals
• Juno Therapeutics
• Juventas Therapeutics
• Kiadis Pharma
• LifeCell
• LifeNet Health
• Living Cell Technologies
• Lonza
• MaxCyte
• Mesoblast
• Nanofiber Solutions
• Nanotope
• Neuralstem
• NewLink Genetics
• Northwest Biotherapeutics
• NovaRx
• Opexa Therapeutics
• Orteq
• Orthofix Holdings
• Osiris Therapeutics
• Pfizer
• Pluristem
• Prima BioMed
• Q Therapeutics
• Regenerex
• Regenerys
• Regience
• Regrow
• RepliCel
• ReproCELL
• RhinoCyte
• Rohto Pharma
• RTI Surgical
• SanBio
• Sangamo Therapeutics
• Shanghai Sunway Biotech
• Shire
• Stratatech
• Synergistic Technologies
• tella
• Tissue Genesis
• TissueGene
• Txcell
• VentriNova
• Vericel
• ViaCyte
• VistaGen Therapeutics

[Market driver]
• CVD and diabetes in young adult and aging population
• For a full, detailed list, view our report

[Market challenge]
• High cost of clinical trial
• For a full, detailed list, view our report

[Market trend]
• Increasing strategic alliances
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Overview of regenerative medicine in the US market

PART 05: Market landscape
• Market overview
• Market size and forecast

PART 06: Pipeline portfolio
• Five forces analysis

PART 07: Market segmentation by product
• Cell therapy market in US
• Tissue scaffolds market in US

PART 08: Market segmentation by application
• Dermatological
• Musculoskeletal
• Ocular
• Cardiovascular

PART 09: Market segmentation by end-user
• Hospitals
• ASCs
• Regenerative medicine centers

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Increasing strategic alliances
• Increasing number of regenerative medicine in product line
• Gene therapy trending toward market expansion

PART 13: Vendor landscape
• Competitive landscape

PART 14: Key vendor analysis
• Acelity
• Medtronic
• MiMedx Group
• Organogenesis
• Zimmer Biomet
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Overview of key sectors involved in regenerative medicine
Exhibit 02: SBIR and STTR programs
Exhibit 03: Regenerative medicine market in US 2016-2021 ($ billions)
Exhibit 04: Pipeline of regenerative medicines for CVDs
Exhibit 05: Pipeline of regenerative medicines for central nervous system, orthopedic, and ocular disorders
Exhibit 06: Pipeline of regenerative medicines for dermatology and diabetes
Exhibit 07: Pipeline of regenerative medicines for oncology
Exhibit 08: Five forces analysis
Exhibit 09: Regenerative medicine market in US by product
Exhibit 10: Regenerative medicine market in US by product 2016 and 2021 ($ billions)
Exhibit 11: Ethical issues involved in different cell therapy research categories
Exhibit 12: Key cell therapy products marketed in US
Exhibit 13: Cell therapy market in US 2016-2021 ($ billions)
Exhibit 14: Market dynamics: Cell therapy market in US
Exhibit 15: Collaborations for R&D of tissue scaffold
Exhibit 16: Tissue scaffolds market in US 2016-2021 ($ millions)
Exhibit 17: Recent M&A in tissue scaffolds market
Exhibit 18: Market dynamics: Tissue scaffolds market in US
Exhibit 19: Regenerative medicine market in US by application 2016 (%)
Exhibit 20: Market growth: Regenerative medicine market in US by application
Exhibit 21: Overview of dermatological in regenerative medicine market in US
Exhibit 22: Target population and market growth opportunity
Exhibit 23: Pipeline of regenerative medicine for dermatological
Exhibit 24: Overview of musculoskeletal in regenerative medicine market in US
Exhibit 25: Regenerative medicine for occupational injury and sports injury
Exhibit 26: Pipeline of regenerative medicine for musculoskeletal
Exhibit 27: Overview of ocular in regenerative medicine market in US
Exhibit 28: Market overview of CVDs in US
Exhibit 29: Overview of cardiovascular in regenerative medicine market in US
Exhibit 30: Regenerative medicine market in US by end-users 2016
Exhibit 31: Segmentation of hospitals based on number of beds
Exhibit 32: Revenues funded by federal agencies for regenerative medicine research in 2014 ($ millions)
Exhibit 33: Estimated budget of funding for research in regenerative medicines 2012-2017 ($ millions)
Exhibit 34: Regulatory challenges in regenerative product market
Exhibit 35: Major strategic alliances in regenerative medicine market globally
Exhibit 36: Some of the mid and late stage pipeline products for regenerative medicine
Exhibit 37: Competitive structure analysis of regenerative medicine market in US 2016
Exhibit 38: Competitive landscape of regenerative medicine market in US 2016
Exhibit 39: Strategies for large and small companies in regenerative medicine market in US
Exhibit 40: Key recommendations for new entrants in regenerative medicine market in US
Exhibit 41: Acelity: Key highlights
Exhibit 42: Acelity: Strength assessment
Exhibit 43: Acelity: Strategy assessment
Exhibit 44: Acelity: Opportunity assessment
Exhibit 45: Medtronic: Key highlights
Exhibit 46: Medtronic: Strength assessment
Exhibit 47: Medtronic: Strategy assessment
Exhibit 48: Medtronic: Opportunity assessment
Exhibit 49: MiMedx Group: Key highlights
Exhibit 50: MiMedx Group: Strength assessment
Exhibit 51: MiMedx Group: Strategy assessment
Exhibit 52: MiMedx Group: Opportunity assessment
Exhibit 53: Organogenesis: Key highlights
Exhibit 54: Organogenesis: Strength assessment
Exhibit 55: Organogenesis: Strategy assessment
Exhibit 56: Organogenesis: Opportunity assessment
Exhibit 57: Zimmer Biomet: Key highlights
Exhibit 58: Zimmer Biomet: Strength assessment
Exhibit 59: Zimmer Biomet: Strategy assessment
Exhibit 60: Zimmer Biomet: Opportunity assessment
Exhibit 61: Other prominent vendors: Regenerative medicine market in US


Acelity, Medtronic, MiMedx, Organogenesis, Zimmer Biomet, ACE Surgical Supply, Acera Surgical, Acologix, Advanced Biologics, AlloCure, AlloSource, Alphatec Spine, ANTEROGEN, Antibe Therapeutics, Astellas Pharma, Athersys, Avita Medical, AxoGen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, Biogen, BioRestorative Therapies, Biostage, Bio-Tissue, BioTissue, bluebird bio, BONESUPPORT, BrainStorm Cell Therapeutics, Caladrius, Calimmune, Capricor Therapeutics, CELGENE, Cell Medica, Cell Therapy, CellBioMed, CellSeed, Celyad, CESCA THERAPEUTICS, CTM CRC, CryoLife, Cynata, Cytori Therapeutics, Dendreon Pharmaceuticals, DiscGenics, Fate Therapeutics, Fibrocell Science, Forticell Bioscience, Fortress Biotech, FUJIFILM Holdings, Gamida Cell, Geron, GlaxoSmithKline, Healthpoint, Histogen, Histogenics, Holostem Terapie Avanzate, Humacyte, Immunocellular Therapeutics, Integra LifeSciences, Intercytex, InVivo Therapeutics, iSTO Biologics, Janssen Pharmaceuticals, Juno Therapeutics, Juventas Therapeutics, Kiadis Pharma, LifeCell, LifeNet Health, Living Cell Technologies, Lonza, MaxCyte, MEDIPOST, Mesoblast, Nanofiber Solutions, Nanotope, Neuralstem, NewLink Genetics, Northwest Biotherapeutics, NovaRx, Opexa Therapeutics, ORGANOVO HOLDINGS, Orteq, Orthofix Holdings, Osiris Therapeutics, Pfizer, PHARMICELL, Pluristem, Prima BioMed, Q Therapeutics, Regenerex, Regenerys, Regience, Regrow, RENOVA THERAPEUTICS, RepliCel, ReproCELL, RhinoCyte, Rohto Pharma, RTI Surgical, SanBio, Sangamo Therapeutics, Shanghai Sunway Biotech, Shire, Stratatech, SURGILOGIX, Synergistic Technologies, TAKARA BIO, tella, Tissue Genesis, TissueGene, Txcell, VentriNova, Vericel, ViaCyte, and VistaGen Therapeutics.